Thursday, October 15, 2026

Crude Oil Futures Is 3% Down In The Last 10 Sessions

ViaNews Editorial Team

February 5, 2024

Crude Oil Futures Is 3% Down In The Last 10 Sessions

(VIANEWS) - Crude Oil (CL) has been up by 3.85% for the last 10 sessions. At 01:50 EST on Monday, 5 February, Crude Oil (CL) is $72.51.

Volume

Today's last reported volume for Crude Oil is 31788, 99.99% below its average volume of 14156284155.59.

Volatility

Crude Oil's last week, last month's, and last quarter's current intraday variation average was 0.83%, 0.47%, and 1.51%, respectively.

Crude Oil's highest amplitude of average volatility was 1.44% (last week), 1.39% (last month), and 1.51% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Crude Oil's commodity is considered to be overbought (>=80).

Previous days news about Crude Oil (CL)

  • WTI crude oil weekly forecast: mid-term support challenged as risks escalate - 04 February 2024. According to DailyForex on Sunday, 4 February, "Having heard of an attack on an oil tanker on Friday the 26th of January, the price of WTI Crude Oil surged higher, and over that weekend a U.", "Forex Brokers We Recommend in Your Region See full brokers list 1 Read full review Get Started BrokerGeoLists.push({type:'ReviewsNonPartner',id:'horizontal-top-5',size:5,fullReviewText:`Read full review`,getStartedText:`Get Started`,readReviewText:`Review`});Commodity Trading in WTI Crude Oil has Complex Mechanics"

More news about Crude Oil (CL).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com